Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 20.3% in March

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 115,700 shares, an increase of 20.3% from the March 15th total of 96,200 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average trading volume of 72,800 shares, the short-interest ratio is presently 1.6 days.

Institutional Trading of Avalo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in shares of Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after purchasing an additional 94,742 shares during the last quarter. Bank of Montreal Can purchased a new position in Avalo Therapeutics during the fourth quarter worth $446,000. Walleye Capital LLC acquired a new position in shares of Avalo Therapeutics in the fourth quarter worth $145,000. Affinity Asset Advisors LLC lifted its position in shares of Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after acquiring an additional 505,765 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Avalo Therapeutics during the fourth quarter valued at $114,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AVTX. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Piper Sandler assumed coverage on Avalo Therapeutics in a research note on Friday, February 28th. They set an “overweight” rating and a $48.00 target price for the company. Jefferies Financial Group initiated coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Stifel Nicolaus started coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $36.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Stock Down 4.8 %

NASDAQ:AVTX opened at $4.41 on Monday. Avalo Therapeutics has a 52-week low of $4.31 and a 52-week high of $17.49. The stock has a fifty day simple moving average of $6.90 and a 200-day simple moving average of $8.69.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.